The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ⋯ Early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19. (Funded by Merck Sharp and Dohme; MOVe-OUT ClinicalTrials.gov number, NCT04575597.).
-
Randomized Controlled Trial Multicenter Study
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery in an earlier analysis of this phase 3 trial of neoadjuvant and adjuvant therapy. The primary results regarding event-free survival in this trial have not been reported. ⋯ In patients with early triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab after surgery, resulted in significantly longer event-free survival than neoadjuvant chemotherapy alone. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
-
Randomized Controlled Trial Multicenter Study
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Nuvaxoid is safe and 90% effective against the Alpha (B.1.1.7) SARS-CoV-2 variant.
pearl